| Title |
Date |
| Hewitt: statement on Pharmacies "Control of Entry" Reforms |
14 June 2006 |
|
Response of the National Pharmacy Association to ARM 33
|
12 October 2005 |
|
Consultation on strengthened governance arrangements for the safe management of controlled drugs
|
29 September 2005 |
|
Response to proposals to reform and modernise pharmaceutical services legislation in England (Gateway number: 5141)
|
21 September 2005 |
|
Response of the National Pharmacy Association to ARM 30
|
8 August 2005 |
|
NPA response to MLX 321 - proposals to introduce independent prescribing by pharmacists
|
25 May 2005 |
|
NPA response to MLX 320 on options for the future of independent prescribing by Extended Formulary nurse prescribers
|
25 May 2005 |
|
Response of the National Pharmaceutical Association: Reimbursement of “standard” branded generic medicines
|
14 April 2005 |
|
Making the best use of the pharmacy workforce: a consultation paper
|
28 March 2005 |
|
NPA response to MLX 313 (Proposed amendments to medicines legislation to allow supply of water for injection by people employed in needle exchange schemes)
|
14 January 2005 |
|
NPA response to ARM 26(Request to raise GSL pack size limit for Dulco-lax Tablets (bisacodyl 5mg))
|
14 January 2005 |
|
NPA response to ARM 25 consultation (Request to reclassify Chloramphenicol Eye Drops 0.5% from POM to P)
|
7 January 2005 |
|
Independent prescribing by community pharmacists – quality, choice and access – NPA position paper
|
3 December 2004 |
|
NPA response to ARM 24 consultation (Proposal to reclassify Benadryl Allergy Relief as a GSL product)
|
17 November 2004 |
|
Summary of Health Select Committee hearing on: "The Influence of the Pharmaceutical Industry" at which NPA Chief Executive 'John D'Arcy, spoke as a witness
|
11 November 2004 |
|
NPA Response to MLX 309 (Implementation of Revised EU Medicines Legislation: Implementing the "2001 Review")
|
21 September 2004 |
|
NPA Response to ARM 23 (Request to reclassify Calpol Infant Suspension, Calpol Sugar Free Infant Suspension and Calpol Six Plus Fastmelts from P to GSL)
|
17 September 2004 |
|
NPA Response to ARM 22 (Request to reclassify Germoloids HC Spray from P to GSL)
|
8 September 2004 |
|
NPA Response to MLX 306 (Proposals for Amendments to the Range of Medicines Which Can be Sold, Supplied or Administered by Optometrists)
|
9 August 2004 |
|
Response of the National Pharmaceutical Association to MLX 305 (Supplementary Prescibers)
|
29 July 2004 |
|
NPA Response to ARM 21 (Request to reclassify Voltarol Pain-Eze Emulgel from P to GSL)
|
27 July 2004 |
|
Response of the National Pharmaceutical Association to Consultation MLX 303 (Nurse Rx Extension)
|
13 July 2004 |
|
Response of the National Pharmaceutical Association to Consultation MLX 304 (Prisons Response)
|
13 July 2004 |
|
Response of the National Pharmaceutical Association to Consultation MLX 308
|
22 June 2004 |
|
NPA Response to ARM 20 (request to reclassify Wasp-Eze Spray from P to GSL)
|
22 June 2004 |
|
Choosing health consultation: NPA response
|
1 June 2004 |
|
Response of the National Pharmaceutical Association to consultation MLX302
|
27 May 2004 |
|
Response of the National Pharmaceutical Association to Consultation MLX 300
|
5 May 2004 |
|
Response of the National Pharmaceutical Association for Consultation MLX 298
|
13 April 2004 |
|
NPA Response to ARM 19 Consultation Document: 'Request to reclassify Zovirax Cold Sore Cream from P to GSL'
|
6 April 2004 |
|
Response of the National Pharmaceutical Association to Consultation MLX 301
|
1 April 2004 |
|
NPA Reponse to Proposal to Place Tamiflu (Oseltamivir) on Schedule 11 of the NHS (General Medical Services) Regulations
|
22 January 2004
|
|
NPA Response to ARM 18 Consultation Document: 'Request to reclassify Zocor Heart-Pro from POM to P' (Simvastatin)
|
9 January 2004 |
|
NPA response to balanced package of measures
|
25 November 2003 |
|
NPA Response to ARM 17 Consulation Document: 'Request to reclassify Scopoderm 1.5mg patch from POM to P'
|
25 November 2003 |
|
NPA Response to ARM 16 Consulation Document: 'Request to reclassify Lamisil AT 1% Spray and Lamisil AT Cream from P to GSL'
|
25 November 2003 |
|
NPA Response to ARM 15 Consultation Document: 'Request to reclassify MIKA-Fenac from POM to P'
|
25 November 2003 |
|
NPA Response to ARM 14 Consultation Document: 'Request to reclassify Anbesol Adult Strength Gel from P to GSL'
|
5 November 2003 |
|
NPA response to: "A Vision for Pharmacy in the New NHS"
|
30 October 2003 |
|
NPA Response to ARM 11 Consultation Document: 'Request to Canesten Combi from P to GSL'
|
21October 2003 |
|
NPA Response to ARM 12 Consultation Document: 'Request to reclassify Galpharm Hayfever & Allergy Relief Syrup and Galpharm Hayfever & Allergy Relief Tablets from P to GSL'
|
14 October 2003 |
|
NPA Response to Choice Responsiveness and Equity consultation
|
9 September 2003 |
|
Response by the NPA to the Report by Auditor General for Wales (The Procurement of Primary Care Medicines)
|
27 June 2003
|
|
NPA Response to ARM 7 Consultation Document: 'Request to reclassify Omeprazole 10mg Gastro-resistant tablets from POM to P
|
23 June 2003 |
|
NPA Position on RCN Congress Resolution on the Need for Regulation of Assessment for Emergency Contraception
|
23 March 2003 |
|
NPA Response to OFT Report into Pharmacy Services
|
February 2003 |
|
NPA Condemns Office of Fair Trading Report into Pharmacy Services
|
20 January 2003 |
